No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study

Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per d...

Full description

Bibliographic Details
Main Authors: Benoît Pilmis, Olivier Jiang, Assaf Mizrahi, Jean-Claude Nguyen Van, Julie Lourtet-Hascoët, Olivier Voisin, Erwan Le Lorc’h, Sidonie Hubert, Elodie Ménage, Philippe Azria, Marie-Françoise Borie, Annabelle Mahé, Jean-Jacques Mourad, Eloïse Trabattoni, Olivier Ganansia, Jean-Ralph Zahar, Alban Le Monnier
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:International Journal of Infectious Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221000357
id doaj-aaa0cdaed1a845d4a32c7fe81069731f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Benoît Pilmis
Olivier Jiang
Assaf Mizrahi
Jean-Claude Nguyen Van
Julie Lourtet-Hascoët
Olivier Voisin
Erwan Le Lorc’h
Sidonie Hubert
Elodie Ménage
Philippe Azria
Marie-Françoise Borie
Annabelle Mahé
Jean-Jacques Mourad
Eloïse Trabattoni
Olivier Ganansia
Jean-Ralph Zahar
Alban Le Monnier
spellingShingle Benoît Pilmis
Olivier Jiang
Assaf Mizrahi
Jean-Claude Nguyen Van
Julie Lourtet-Hascoët
Olivier Voisin
Erwan Le Lorc’h
Sidonie Hubert
Elodie Ménage
Philippe Azria
Marie-Françoise Borie
Annabelle Mahé
Jean-Jacques Mourad
Eloïse Trabattoni
Olivier Ganansia
Jean-Ralph Zahar
Alban Le Monnier
No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
International Journal of Infectious Diseases
Gut microbiota
Third generation cephalosporin
Extended spectrum beta-lactamase
author_facet Benoît Pilmis
Olivier Jiang
Assaf Mizrahi
Jean-Claude Nguyen Van
Julie Lourtet-Hascoët
Olivier Voisin
Erwan Le Lorc’h
Sidonie Hubert
Elodie Ménage
Philippe Azria
Marie-Françoise Borie
Annabelle Mahé
Jean-Jacques Mourad
Eloïse Trabattoni
Olivier Ganansia
Jean-Ralph Zahar
Alban Le Monnier
author_sort Benoît Pilmis
title No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
title_short No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
title_full No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
title_fullStr No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
title_full_unstemmed No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study
title_sort no significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: a pilot study
publisher Elsevier
series International Journal of Infectious Diseases
issn 1201-9712
publishDate 2021-03-01
description Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli (Enterobacteriaceae) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance.
topic Gut microbiota
Third generation cephalosporin
Extended spectrum beta-lactamase
url http://www.sciencedirect.com/science/article/pii/S1201971221000357
work_keys_str_mv AT benoitpilmis nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT olivierjiang nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT assafmizrahi nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT jeanclaudenguyenvan nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT julielourtethascoet nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT oliviervoisin nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT erwanlelorch nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT sidoniehubert nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT elodiemenage nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT philippeazria nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT mariefrancoiseborie nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT annabellemahe nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT jeanjacquesmourad nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT eloisetrabattoni nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT olivierganansia nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT jeanralphzahar nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
AT albanlemonnier nosignificantdifferencebetweenceftriaxoneandcefotaximeintheemergenceofantibioticresistanceinthegutmicrobiotaofhospitalizedpatientsapilotstudy
_version_ 1724201409454276608
spelling doaj-aaa0cdaed1a845d4a32c7fe81069731f2021-03-27T04:25:55ZengElsevierInternational Journal of Infectious Diseases1201-97122021-03-01104617623No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot studyBenoît Pilmis0Olivier Jiang1Assaf Mizrahi2Jean-Claude Nguyen Van3Julie Lourtet-Hascoët4Olivier Voisin5Erwan Le Lorc’h6Sidonie Hubert7Elodie Ménage8Philippe Azria9Marie-Françoise Borie10Annabelle Mahé11Jean-Jacques Mourad12Eloïse Trabattoni13Olivier Ganansia14Jean-Ralph Zahar15Alban Le Monnier16Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France; Service de Maladies Infectieuses et Tropicales, Hôpital Necker–Enfants Malades, Paris, France; Institut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Corresponding author at: Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond, Losserand, 75014 Paris, France.Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceInstitut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService de Médecine Interne, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService d’Accueil des Urgences, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceService d’Accueil des Urgences, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceIAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France; Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, FranceInstitut Micalis, UMR 1319, Université Paris-Saclay INRAe, AgroParisTech, Chatenay-Malabry, France; Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, FranceBackground: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli (Enterobacteriaceae) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance.http://www.sciencedirect.com/science/article/pii/S1201971221000357Gut microbiotaThird generation cephalosporinExtended spectrum beta-lactamase